BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
345.22
+2.29 (+0.67%)
At close: 4:00PM EDT

344.49 -0.73 (-0.21%)
After hours: 4:54PM EDT

Stock chart is not supported by your current browser
Previous Close342.93
Open341.00
Bid339.50 x 2200
Ask346.50 x 1400
Day's Range339.19 - 346.78
52 Week Range249.17 - 388.67
Volume724,906
Avg. Volume1,828,120
Market Cap69.542B
Beta1.40
PE Ratio (TTM)24.51
EPS (TTM)14.08
Earnings DateOct 22, 2018 - Oct 26, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est389.31
Trade prices are not sourced from all markets
  • Biogen Expected to Report Robust Rise in Diluted EPS in 2018
    Market Realist8 hours ago

    Biogen Expected to Report Robust Rise in Diluted EPS in 2018

    In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.

  • Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?
    Zacks9 hours ago

    Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?

    Is (BIIB) Outperforming Other Medical Stocks This Year?

  • Analyst Recommendations for Biogen and Its Peers in August
    Market Realist11 hours ago

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.

  • Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
    Zacksyesterday

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

  • Reuters3 days ago

    Express Scripts staking out million-dollar gene therapies

    Now it is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs. Express Scripts is in talks with biotechnology companies Biomarin Pharmaceutical Inc (BMRN.O), Spark Therapeutics Inc (ONCE.O) and Bluebird Bio Inc (BLUE.O) to have its specialty pharmaceutical business exclusively distribute their new haemophilia therapies when they are expected to become available in 2019 and 2020, Chief Medical Officer Steve Miller told Reuters in an interview.

  • MarketWatch3 days ago

    Bridgewater adds Alibaba, Amazon, Baidu, keeps large gold holdings

    MARKET PULSE Hedge-fund giant Bridgewater Associates, with about $160 billion under management, has added 84,629 shares of Alibaba Group Holding Ltd. (baba) worth some $15.7 million, to its holdings, according to a regulatory filing on Tuesday.

  • Reuters4 days ago

    Biogen's pricey muscle drug Spinraza too costly for Britain

    Biogen's (BIIB.O) muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.

  • Reuters4 days ago

    Biogen's pricey muscle drug Spinraza too costly for Britain

    Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. Spinraza, which has a U.S. list price of $750,000 in the first year of treatment, is a big money-spinner in Biogen's home market.

  • There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong
    MarketWatch4 days ago

    There’s new evidence that the dominant approach to Alzheimer’s may be completely wrong

    Experts are questioning a major scientific theory of the disease, which could mean two Biogen drugs won’t be successful.

  • Why Biogen's Stock Ripped Higher in July
    Motley Fool6 days ago

    Why Biogen's Stock Ripped Higher in July

    Biogen's stock got a boost from two material events last month.

  • Investopedia7 days ago

    4 Biotech Stocks That May Fall By as Much as 13%

    Biotech stocks have been hot since the beginning of May, rising by about 13% as measured by the iShares Nasdaq Biotechnology ETF ( IBB), more than double the pace of the S&P 500's rise. Shares of Intercept Pharmaceuticals Inc. ( ICPT) have risen by more than 63% since the beginning of May, while recently posting better-than-expected quarterly results that beat on both the top and bottom lines. The stock has run into a level of technical resistance around $118, posing as the first issue. Additionally, the relative strength index is showing signs that the stock is now overbought, rising above 70 three times since the start of June.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks7 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist8 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist8 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript
    Motley Fool8 days ago

    Ionis Pharmaceuticals (IONS) Q2 2018 Earnings Conference Call Transcript

    IONS earnings call for the period ending June 30, 2018.

  • Morningstar9 days ago

    What Separates Primecap Odyssey Growth From the Rest?

    The following is our latest Fund Analyst Report for Primecap Odyssey Growth POGRX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Primecap Odyssey Growth is one of a select number of funds run by Primecap Management, whose fundamentals-based multimanager approach richly rewards long-term investors.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist9 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit9 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    Biogen Inc NASDAQ/NGS:BIIB

  • Benzinga10 days ago

    Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate

    The Street leans bullish on Biogen Inc (NASDAQ: BIIB ), and one sidelined analyst doesn’t want to miss on the profits. The Rating Stifel Nicolaus analyst Paul Matteis resumed coverage of Biogen with a ...

  • Analysts Are Bullish on Sarepta Therapeutics
    Market Realist10 days ago

    Analysts Are Bullish on Sarepta Therapeutics

    Wall Street analysts estimate Sarepta will report a net loss of $0.89 per share on revenues of $71.6 million in Q2 2018, which is more than a 100% YoY increase in revenues as compared to $35.0 million during the second quarter of 2017. Wall Street analyst estimates suggest the stock has the potential to return ~51.4% over the next 12 months. As of August 6, 19 analysts were tracking Sarepta Therapeutics stock.

  • Recent Product Approvals Bode Well for Bristol-Myers Squibb
    Market Realist10 days ago

    Recent Product Approvals Bode Well for Bristol-Myers Squibb

    Bristol-Myers Squibb (BMY) has key licensing arrangements with Biogen (BIIB) and Roche Holding (RHHBY). It out-licensed the exclusive rights to develop and commercialize BMS-986168 to Biogen in the second quarter of 2017. This compound is in development for the treatment of progressive supranuclear palsy.

  • What to Expect from Sarepta’s Second-Quarter Earnings
    Market Realist10 days ago

    What to Expect from Sarepta’s Second-Quarter Earnings

    Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company. Sarepta develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases.

  • 5 Stocks That Should Start Paying Dividends
    Kiplinger11 days ago

    5 Stocks That Should Start Paying Dividends

    Investors tend to be drawn to hot technology and biotechnology stocks for their growth prospects - not for the cash they return to shareholders. But several well-known tech and biotech stocks could afford to invest in their businesses, buy back their shares and pay dividends, if only they chose to. When it comes to returning cash to shareholders, corporate management often prefers stock buybacks to dividends because it gives them flexibility. A company can adjust its share repurchases according to business and market conditions. A dividend is a commitment. The market often exacts severe and swift revenge if a company cuts or suspends its payout. The initiation of a dividend can also be taken as a sign that a company or stock's best days are behind it. A quick look at Apple's (AAPL) performance shows that's not necessarily the case. The company reinstated its dividend in 2012 after a 17-year hiatus. Between price appreciation and payouts, Apple stock has delivered a total return of about 170% since March 2012, when it announced plans to reinstate its dividend later that year - the Standard & Poor's 500-stock index is up about 130% over the same span, including dividends. The following five stocks don't yet offer dividends, but they should ... and could. Each has the cash-generation ability to start a regular payout without giving up on share repurchases and investments in future growth. SEE ALSO: 53 Best Dividend Stocks for 2018 and Beyond

  • S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks
    Zacks11 days ago

    S&P 500 Posts 5th Straight Weekly Gain: 5 Great Picks

    U.S. corporates have so far posted robust results for second-quarter 2018, maintaining the terrific earnings momentum which has begun since the first-quarter 2018.

  • Stifel: Biogen can rally to $394
    CNBC Videos10 days ago

    Stifel: Biogen can rally to $394

    The "Halftime Report" traders debate Stifel's bullish call on Biogen in the "Call of the Day."